Enanta Pharmaceuticals, Inc. (ENTA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
500 Arsenal Street
Watertown, MA 02472
United States of America (the)
Phone
617 607 0800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
131
First IPO Date
March 21, 2013
| Name | Title | Pay | Year Born |
| Jay R. Luly | President, Chief Executive Officer & Director | 742,273 | 1956 |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 496,852 | 1978 |
| Matthew Kowalsky | Chief Legal Officer & Corporate Secretary | 575,652 | 1973 |
| Brendan Luu | Chief Business Officer | 622,856 | 1975 |
| Nathaniel S. Gardiner | Consultant | 672,675 | 1954 |
| Yat Sun Or | Chief Scientific Officer | 814,285 | 1952 |
| Scott T. Rottinghaus | Chief Medical Officer | 863,706 | 1974 |
| Harry R. Trout | VP of Finance & Interim Principal Financial Officer | 0 | 1969 |
| Kathleen S. Capps | Executive Director of Accounting, Controller & Interim Principal Accounting Officer | 0 | 1985 |
| Jennifer Viera | Executive Director of Investor Relations & Corporate Communications | 0 | N/A |
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.